Shares of Immunome, Inc. (IMNM) are rising more than 16% Friday morning after AbbVie (ABBV) and Immunome announced partnership to develop up to 10 novel antibody-target pairs leveraging Immunome's Discovery Engine.
As per the multi-year collaboration agreement, Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from the selected tumors.
Immunome will receive $30 million upfront, with further milestone payments on achieving certain targets.
"This collaboration fits well within Immunome's strategy to maximize the new drug discovery potential of our Discovery Engine through partnerships across multiple therapeutic segments, in addition to advancing our own proprietary pipeline," said Purnanand Sarma, president and CEO of Immunome.
IMNM, currently at $5.50, has traded in the range of $2.09-$12.35 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.